Learn how artificial intelligence is used to design AI antibodies, marking a milestone in protein design and treatment innovation.

Abzena and Mabqi bring together two organizations that are focused on advancing antibody innovation through integration.

Abzena, an integrated CDMO for complex biologics and bioconjugates, and Mabqi, a biotechnology company focused on developing fully human antibodies, formed a strategic partnership.

Abzena, the leading end-to-end integrated CDMO for complex biologics and bioconjugates, and Mabqi, a biotechnology company focused on the discovery and development of fully human antibodies, announced ...

After Pfizer agreed to acquire weight-loss drug developer Metsera for $7.3 billion, Novo Nordisk swooped in with an ...

Advances in MM management have improved survival, but challenges remain for patients progressing after three therapy lines. New therapies like CAR T-cell and bispecific antibodies require integration ...

The webinar highlights advances in high-throughput gene and protein synthesis platforms that accelerate antibody discovery and optimization. Using accurate HTP Strings DNA fragments improves cloning ...

ImmunoPrecise Antibodies (IPA) has announced the opening of its new, innovative full-service B-cell facility offering B-cell screening, sorting and sequencing on a broad range of therapeutically ...